Medical Intern s Handy Notes

8/17/2019 Medical Intern s Handy Notes

1/23

EMERGENCY DRUGS

Epinephrine 0.01-0.03 mkd q3-5min Atropine 0.02-0.03 mkd(max0.5mg)

Adenocard 6 mg initially 12mg nxt

Adenosine 6mg/2mL!a "l#c 10$ 0.1-0.2 mkd!aptopril 0.3-0.5 mkd q6-12h Capoten 25mg/tab%ydrala&ine 0.1-0.2 mkd Apresoline PO: 10mg; 25

IV: 20mg/amp'-!arnitine 50 mkd q-6h() 30-0mkd** Carnicor PO: 1/10; 0 IV: 1/5 'idocaine 1.0 mkd +ol#,

20-50 #gminannitol 20$ 1-2 mkd /rep 1.2$ ,oln (1 medm')

a%!3 1.5-2.0 mkdaloxone 0.1 mkd Plain 0!"mg/1mL #eonatal 0!02mg/1mLiedipine 0.25-0.5 mkdq-6hipride 0.5-1.5 #gkm4recholine 2.mgm2d q /

CEPHALOSPORINS 1st Generation

!ephalexin 25-100 mk7 q6-h 250-500!eadroxil 30 mk7 897(max:2g)!ealothin 50-100 mk7 ;97

!ea&olin 50-100 mk7 q!ephradine 50-100 mk7 q6-12

2nd Generation!eamandole 50-100 ;97!eaclor 20-0 mk7 q-12 Ceclor 125/5; 250/5 $%!e#roxime 9 100mkd q 12%1g q-12 or ? 12yo @ 2g-ad#lt,

Cla&oran 500mg; 1g; 2g

!etriaxone 8 50->5mk77 !hild: 50->5 mk7 7eningiti, '7:>5mkd0-100mk7q12-2

Ad#lt: 1-2 g 7

AMINOGLYCOSIDES

Amikacin 10-15 mk715-25mk7q-12 Prep: 100/2; 250/2 anamycin 30-50 mk7

Bo+ramycin 6- mk7 (e+cin)"entamycin 5- mk7 9<

MACROLIDES

Erythromycin 30-50 mk7'r(t)rocin 200/5; "00/5 ds; 100/2!5gtts

A&ithromycin 10 mk7 7x175mk7x7 "rp. A Ctrep 12mk7x5 7

!lar ithromycin 15 mk7 q12 or

>.5 mkd *laricid 125/5 +don,t re&-


2/23

ANTI-STAPH

acillin 100-200 mk7 q6 Vigopen 250/5 !o-AmoxiclaD 0-60 mk7

A.gmentin 156/5; 12/5 Ctaloxin 100-200 mk7


3/23

ANALGESICS

Hentanyl 'o: 2 mk7 od: 2-20 mk7

%igh: 2-50 mk7 C#+lima&e (Ian,,en): 50#g2m'9+#proen 5-10 mkd q6- $olan P 100/5 eenamic acid 3-5 mk7 Ponstan 50/5 ida&olam 0.1 mk7 $ormic.m IV: 5/1;5/5;15/

PO: 5mg/taborphine 0.1-0.2 mk7 orp)ine 10/mLal+#phine 0.1 mk7 #.bain 10/mL/anc#roni#m 0.0-0.1 mk7/rometha&ine

P)energan IV: 50/2 PO: 1/1; 10mg

*etorolac 0!25 m8d 9 6 )rs

PENICILLINS

/!: 50-100B47 or 25-30 mk7

625mg G 1 4 2505 G 00 B4 312.55G 500 B4 500mg G 00 B4ral /! 100-200 B47 Pentacillin 50/5; 500mg %.mapen 25/5; 250; 500 egapen 50 4/mL gtts

12!5/5; 625mg Amoxicillin 20-50 mk7 q

0-0mk7-acillin 100-200 mk7q6Ctaloxin 100-200 mk7

Ampicillin 100-200 mk7(8: 50-100 897

men: 300-00 mkd q6)Unas6n 2$ #&D ' 7 )rs Ampicin/Pentre(l/Aldribid8acampicillin 25-50 mk7 Penglobe 200/5

ANTI-HELMINTHICxantel pamoate 10-20 mkd .antrel 100/5; 100 Betrami&ole 2.5-5 mkd C7 4< 25mg/10mL

e+enda&ole 100 mkd 897 x 3 day, Antio: 100; 500mg/tab; 20mg s.sp

Combantrin 125mg; 250mg/tab 125mg/5mL s.sp

?15yo G 500 mg 10-1yo G 3>5 mg 5- yo G 250 mg 5 yo G 125 mg

ANTI-8IRALethi,oprinol 50-100 mk7 Isoprinosine 250/1; 500 9no,iplex 50 mk7 Imm.nosine 250/5

Amantadine 5- mk7

%(mmetrel 50/5


4/23

ANTI-ASTHMA Aminophylline '7: -10 mk

7: 3-57rip: 0.-0. mk%

eonate: 1 mkd q or 2 mkd q12

Apnea: '7: 5-6 mkd (o.5-0. mkhrin#,ion)

7: 2 mk 12h po,t-'7 /rep: 25010 7rip: eg: 5kg at 0. mk% in h drip:

5 x 0. x G 16mg in hi 9I$1@5mg/mL

DIA5EPAM DRIP

0.3 mk% dil#te in CC make, 0.1mgm'conc G mgtotal Dol (m'


5/23

ANTI-HISTAMINES7iphenhydramine 3-5 mk7 B97-;97 >enadr(l IV: 50/1 dose

PO: 12!5; 25; 50 ethdila&ine 0.3 mk7 q12-q6

4acar(l "/5; "; = !lema,tine 0.05 mk7 q12 4a3eg(l 0!5/5; 1mg %ydroxy&ine 1 mk7 Itera 2mg/ml; 10; 25 !etiri&ine 0.25 mk7 Virli 10mg/1mL'oratadine 2-12yo = 30k: 1 t,p 7

?30k: 2 t,p 7 Claritin 5mg/5mLetotien 0.025 mkd q12


6/23

STEROIDS

7exametha,one 0.2-0. mkd $ecadron "/1%ydrocorti,one '7: 10 mk

7: 5 mk7 %ol.corte& 100/2; 250/2

Acto3ial 100 /redni,olone 0.> mk7 %ol.medrol 125/2 /redni,one 0.5 mk7 1 mk7 (8A)ethylpredni,olone 1.5 mk7 q 6 hr,

ALUMIN

Al+#min: 1 gdo,e Al+#rein 12.5g50m' (25$)

Horm#la: 7e,ired-Act#al x 1.2 x Ft Al+#min 0.5-1.0 g (max 6 g7) Alb.mer/Alb.tein 50/1 +5-

250/1 +25-

ELECTROLYTES


7/23

LUMAR TAP/re,,#re (in cm%2)" 22 (1 K) G gtt, in 21 ,ec" 22 (3 K) G gtta in 3 ,ec" 20 (3 K) G gtt, in 12 ,ec

F8! correction in tra#matic tap:/eriph F8! x 1000 G F8! 5000000 1000 L8!

!9: increa,ed 9!/ ,eDere !/ depre,,ion inected ,kin decrea,ed platelet co#nt or +lood do +rain a+,ce,,

ooress: $%-(% ##H2o: ;C $$? o! /ood @0ose

PHOTOTHERAPY9ndication: /B: 10 mg$ +ilir#+in

HB: 15 mg$ +ilir#+in!omplication,:

o,motic diarrheara,he,+ron&e +a+y ,yndromedehydration

HS METHOD !or I89 In!0sion

2.5-10kg 100cckday10-20kg 1000ccJ50cck oDer 10k?20kg 1500ccJ20cck oDer 20k

BH G cchr or #gttmin

/hototx J20$Bachypnea J25-50$HeDer J12$ q 1o! ? 3>.5o!%ypermeta+olic J25-50$8#rn, J1$ or 1,t 7egreeCeating J10-25$


8/23

SA ;t + * > + *%% rena4 ;t F%

en CA x 1500/reterm CA x 1200

!%H CA x 00!ardiac CA x 200Lenal CA x 00 J 2h 4H = 2yo G CA x 1500

? 2yo G CA x 1200

0-5 kg t x 0.05 J 0.056-10 kg t x 0.0 J 0.110-15k t x 0.03 J 0.215-20k t x 0.02 J 0.3

CRITERIA 9OR RHEUMATIC 9E8ER

aOor: carditi, polyarthriti, chorea,#+c#taneo#, nod#le, erythema marginat#m

inor: hx o LHL%7 arthralgia eDereleDated AC !L/ @ ECL prolonged/L interDal (J) c#lt#re o "rp. A ,trep

RANSONS CRITERIA !orACUTE PANCREATITIS

On Ad#ission,

1. age ? 55 yr,2. le#kocyto,i, ? 160003. hyperglycemia ? 200mgd'

(11mmol'). ,er#m '7% ? 00 94'5. ,er#m ACB ? 250 94'

D0rin@ t)e initia *()rs,

1. hematocrit all ? 10$2. l#id ,eq#e,tration ? 000 m'3. hypocalcemia = mgd' (1.mmol'). hypoxemia (/2 =60mm%g)5. 84 ri,e ?1.5mgd' (?1.mmol') po,t 9-10day,


9/23

% G ∆ 2 x p!2%!3

!hronicity: ∆% P 0 i = 0.3 G chronic

p!2 0.3-0.> G acchr ? 0. G ac#te

xygenation: 0-100 adeq#ate 60-0 mild hypoxemia 0-60 moderate = 0 ,eDere

CPAP

BHL G t x B


10/23

IA479!E

!linical Ia#ndicemanie,tation o color ,tartingat ,er#m +ilir#+in leDel, 5-> mg$

!riteria to r#le o#t phy,iologic Oa#ndice:1. !linical Oa#ndice in the 1,t 2 hr, o

lie.2. 9ncrea,e in total ,er#m +ilir#+in at

? 5 mgd'day (5 #mol').3. Botal ,er#m +ilir#+in ? 12 mgd' in #ll term and ? 15 mgd' in

preterm.. 7irect +ilir#+in ? 1.5-2 mgd'

(26-3 #mol').5. Ia#ndice la,ting or more than 1

eek or term 2 eek, orpreterm.


11/23

CARI

2#o-2 6o,Mid Pne0#onia, ,end home B/-CQ

Bx eDer -#p in 2- day,

Se.ere Pne0#onia, Admit giDe 9 hr,)

Mid Moderate Se.ere= 2 yo 50 100 150

? 2 yo 30 60 0

%ydrite 1 ta+ in 100cc ater G h"l#co,t 1 ,achet in 100cc ater G hre,ol 1 ,achet in 1' ater G 2h"l#colyte 1 ,achet in 200cc ater

9LUIDS AND ELECTROLYTES

1. %ypotonic: 75F 75 75 0.3a!l 75 98 9,olyte 75 aintre,ol2. 9,otonic: 75'L 75 CC /'L /CC

3. %ypertonic: 750F 710F

STAGES O9 DH91. He+rile2. Ae+rile3. !onDale,cent

GRADING O9 DH91. HeDer J non-,peciic ,,x (J) to#rniq#et te,t2. "r. 1 J ,pontaneo#, +leeding3. "r.2 J manie,tation, o circ#latory

ail#re: rapid eak p#l,e narrop#l,e pre,,#re %/B cold clammy

extremitie,. /roo#nd Chock ith #ndetecta+le 8/ @ p#l,e

7ay, 1-5: petecchiae eDer 7ay, 5->: +leeding? 7ay 6 : ,hock

CLASSICAL DENGUE 9E8ER1. Bhrom+ocytopenia not = 100B2. %emoconcentration not ? 20$ o

+a,eline


12/23

I8 9LUIDS

a !l %!3 !a /98 25 20 22 23 3 3 0 13 0 16 3 3

CC 15 15'L 130 10 2 3 3L 0 309,olyte 0 35 09,olyte/ 25 20 20/'/ 25 20 220.3$ 51 510.6$ 102 1020.5 >> >>0.$ 15 15LC 0 20 0 30 (20 gl#c)/-lyte0 0 20 0/-lyte /l 5 20 35

a G 1 meq G 23 mg

G 1 meq G 3 .1 mg

I89 O9 CHOICE

'8 /'L


13/23

I;

2-12 mo G age in mo x 10G t in l+,

= 6 mo G age in mo x 600 J 8F

G t in gm,6-12 mo G age in mo x 500 J 8F

G t in gm,= 1 yo G Age (mo) J 2? 2 yo G age in yr, x 2 J

G t in kgG age in yr, x 5 J 1>G t in l+,

.5 G 2 x 8F1 yo G 3 x 8F2 yo G x8F3 yo G 5 x 8F

5 yo G 6 x 8F> yo G > x 8F10 yo G 10 x 8F

MOTOR GRADING

0 no moDement1 licker o contraction ith no

a,,ociated moDement at a Ooint2 moDement pre,ent +#t canTt ,#,tain again,t graDity2 moDement again,t graDity

+#t not ith re,i,tance3 moDement again,t ,ome re,i,tance moDement again,t #ll re,i,tance

COMPOSITION O9 ODY 9LUIDS

a !l %!3"a,tric 50 10-15 150 0

/anc 10 5 50-100 1008ile 130 5 100 09leo,to 130 15-20 120 25-307iarrh 50 35 0 50Ceat 50 5 55 08lood 10 -5 100 254rine 0-100 20-100 >0-100 0

,m G 2 (a meq' J meq') J 4rine mgd' P gl#co,e mgd' 2. 1


14/23

CE

8 5-50 calkg3-10kg 60-010.15 5-65

15.25 0-525.35 35-035.60 30-35? 60 25-30

H G 8!E x Ft x 1.5 G cchr2 or #gttmin

HeDer G J12$ or eDery o!ri,e ? 3>.5o!

%yperDentilationdy,pnea G J 25$8ronchial a,thma G J 50$8ililight therapy G J 20$

CALORIC REUIREMENTS= 1 mo 110-10 calkday1-11 mo, 110-1151-2 yr, 100-1103-6 yr, 0-100

>- yr, 0-010-12 yr, >0-013-15 yr, 55-6516-1 yr, 5-50

PROTEINS RDA0-5 mo, 2.5 gkgday6-11 mo, 2.5-3.01-6 yo 2.0-2.5>-12 yo 1.5-2.013-15 yo 1.516-1 yo 1.0-1.5

il8 orm.la CO# Cimilac 20 cal 1.5100

A 20 1.5100C-26 20 2.25100/re-A 21 21008 22 1.1100Enalac 21 2.25100

in#,ion rate G 9< rate x amt o (mEq) 5 mEq x 3 kg G >5 mEq

3 ,hit,

G >5 mEq G .3 cc G >2 mEq (1 cc G mEq)

9deal tracheal a,pirate: E! =25 /T, ?10

ax ,teroid, or C : 2 mk7 or 60km U -6 k,


15/23

A'' %9"% L9C /LB!'

/%ACE ind#ction con,olidation

maintenance

1217oxor#+icin 25 mgm2 on 70>121/redni,one 0 mgm2 on 721-25-' a,parigina,e 6mgm2 or do,e, (3 do,e, per eek mmt)

Anaphylaxi,

epinephrine.1:10000.01 mkd max o .5 ml 9

diphenhydramine1-2 mkd 99< #p to 50 mg q -6

Lanitidine1-2 mk7 #p to 50 mg 9< q 6%

%ydrocorti,one5-10 mkd #p to 100-500 mg 9< q -6%

AB%L/EBLV1. 8ody Feight

A. 9deal 8ody Feight At +irth 3000 gm, = 6 mo (g) age in mo x 600 J 8F

6-12 mo (g) age in mo x 500 J 8F el,onW,: 3-12 mo, (age in mo J )2 1-6 yr (kg) age in yr x 2 J >-12 (kg) (age in y x >- 5) 2

8. Expected 8ody Feight (#p to 1 mo) Berm E8FG(age in day,-10) x 20 J 8F /reterm E8FG(age in day,-1) x 15 J 8F Fhere: 10Gtime to recoDer oDer

phy,iologic t lo,, 20Ggday gained!. E,tim t

-5mo 2 x 8F 5 yo 6 x 8F 1 yo 3 x 8F > yo > x 8F 2 yo x 8F 10 yo 10 x 8F 3 yo 5 x 8F


16/23

ACB%A !'ACC9H9!AB98ACE7 CE =60/EHL Dar =20 20-30 ?30 ?30HE =60

AB%A C!L9";OODJS SCORE

0 1 2p02 or 50-100 X>0 in X>0 in cyano,i, rm air 0io28reath ,nd, #neq#al a+,ent

Acc m#,cle, mod maxExp hee&e mod extrem

!ere+al xn depre,dcoma agitated

1-3 mild a,thma attack -6 moderate +ed,ide > #p ,eDere int#+ate

SIL8ERMANJS SCORE 0 1 2

Hlaring - min marked'oer che,t Letraction, - Di,i+le marked

4pper che,t Letraction, - ,ynch in- ,ee,a

draingQyphoid retraction, - Di,i+le marked"r#nting - ,teth ear, (a#di+le)

3- giDe 02 Y> int#+ate

/er,onal +e,t /redictiDe 5male,:ht(cm) - 100 x 5 J 1>0

act#al /EH ?0$ normal

!%H !'ACC9H9!AB9

Anatomic9 acq#ired99 congenital

/hy,iologic (di,t#r+ance in) A heart rhythm and cond#ction8 myocardial contraction! clinical ,yndrome (%/7)

H#nctional9 a,ymptomatic99 ,ymptomatic ?ordinary act999 ,ymptomatic minimal actiDity9< ,ymptomatic at re,t

Bherape#tic, A no re,triction o act8 re,triction o ,eDere act

! re,triction o moderate act7 ,harp re,triction o ordinary actZE complete re,t in a chair or +ed


17/23

9' A++otyeth G 1:2 I @ e,tle G 1:1

9' !A' !% g HAB !%alare >2d' 2.5 3.6 >.

+m(t) 6' .0 1.6 >2.> >5dl 1.1 .5 20o&+m (pt) 6>1' 1.0 3.3 66.+onna 22o& 1.1dlcaro ,yr 120o& 31corn oil 13d' 2enalac 6>.6d' 2 3.5 >.

21o& 2.25dlgain 22o& 2.gd'lact#m 21.o& 3.2gd'nan1 6>d' 1 .2 3 .6 > .5

20o& 1.5dlnan ha 6>d' 1.51neo,#re 22o&n#tren Or 100d' 3 3. 13.3

prenan 0d' 2.3 .2 .621o& 2dl

promil 1d' 2. .1 .,26 20o& 2.25dl,26l+ 100 2.d'

125ml2o&

!/A/ "497E'9EC

1. 9nitially !/A/ i, ,et [ 6cm ater. 9 there i, no inc in /2 in 15 min pre,,#re m#,t +e increa,ed in 2cm

increment, to a maxim#m o10cm. (9 +y EBB) or +y 12cm (in

other method).2. 9 there i, an increa,e in /a2 red#ce pre,,#re.3. 9 10-12cm ater pre,,#re i, attained and i /a2 reamin, #nder50 Hi2 m#,t +e increa,ed +y 5-10$ increment,.. !/A/ ail#re i, eDident i /a2 remain, le,, than 50 in 100$ Hi2 ith 10-12cm ater.

9 !/A/ ail, #nder non inDa,iDemethod an EBB m#,t +e in,erted.

9 !/A/ ail, EBB mechanicalDentilation i, indicated.

/arameter, Bo 8e et 8 Feaning1. 9mproDement in !QL2. AA8" ,hoing /2 ?G 50 mm%g3. 8lood /% ?G >.3. /!2 =G 55 mm%g

5. %g+ 12-15g$ or %ct 36-5

Feaning rom !/A/1. 7ecrea,e Hi2 +y 3-5$ eDery time /a2 ? >02. Fith Hi2 o 0$ red#ce pre,,#re +y increment, o 2 cm ater eDery 2-% #ntil pre,,#re o 2-3cm

i, achieDed.3. tran,er ptient to oxygen hood ith Hi2 o 15-50$


18/23

CS9 Nor#a 8a0es

OPENING Press0ree+orn 0-110 mm %29nant =200 mm %2

GLUCOSE/remat#re 2-63 mgdl

(c,-+ld ratio 55-105$)Berm -12 mgdl (c,-+ld ratio -15$)

PROTEIN/remat#re 65-150 mgdlBerm 20-1>0 mgdl

F8! ct/remat#re 0-25 c#mm

(5> $ /,)Berm 0-22 c#mm

(61$ /,)

E'E!BL'VBE !/4BAB9I POTASSIUMnormal G-5.6 meq () deliDerance G 0.1 - 0. meqkg

7eicit G (7-A) x t x 0.6aintenance G 2 x tBotal de G deicit J maintenanceH#ll incorporation: 0meq' or 20meq500cc 9H4C9 LABE deliDery G iD rate x in iD Dol t normalG0.2-0.meqkgIISODIUMmaintenance aG3 x tmaxim#m targetdayG10 meqa G 1 mEq G 2.3 mgdl G 1 mEq G 3.1 mgdla%!03G gr xG650 mgG>.> meq

gr DG325

III CALCIUM normal G -10 meqI8 CHLORIDE normal G -106 meq8 CO2 normal G 15 meq

EB B#+e Ci&e, and 7i,tance, According to 9nant Feight

Feight (gm,) l.7. (mm) 7epth (cm)

500-1000 2.5 >.01000-100 3.0 >.5100-100 3.0 .0100-2200 3.5 .52200-2600 3.5 .02600-3000 3.5 .53000-300 3.5 10.0300-3>00 3.5 10.53>00-100 .0 11.0100-500 .0 11.5?500 .0 12.0


19/23

748'E


20/23

AGEGROUP

FREQUENT PATHOGENS (IN ORDER OFFREQUENCY)

Ne!a"es(#$ %)

G&' s"&e"***'s+ Es*,e&*,a *l+ ",e& g&a%-!ega"e /a*ll+ S"&e"***'s !e'%!ae+ Hae%,l's

!l'e!1ae ("e /+34 !!"a/le)

$67 %

Fe/&le !e'%!a

Res&a"& s!*"al &'s+ ",e& &es&a"& &'ses(a&a!l'e!1a &'ses+ !l'e!1a &'ses+ a8e!&'ses)+S. !e'%!ae+ H. !l'e!1ae ("e /+ 34 !!"a/le)

Ae/&le !e'%!a

C,la%8a "&a*,%a"s+ 9*las%a ,%!s+U&ealas%a '&eal"*'%+ *"%egal&'s

76$2 % Res&a"& s!*"al &'s+ ",e& &es&a"& &'ses(a&a!l'e!1a &'ses+ !l'e!1a &'ses+ a8e!&'ses)+S. !e'%!ae+ H. !l'e!1ae ("e /+ 34 !!"a/le)+ C.

"&a*,%a"s+ 9*las%a !e'%!ae+ g&' As"&e"***'s

265 & Res&a"& &'ses (a&a!l'e!1a &'ses+ !l'e!1a&'ses+ a8e!&'ses)+ S. !e'%!ae+ H. !l'e!1ae("e /+34 !!"a/le)+ 9. !e'%!ae+ C,la%8,la

!e'%!ae+ S. a'&e's+ g&' A s"&e"***'s

56$ & 9. !e'%!ae+ S. !e'%!ae+ C. !e'%!ae+ H.!l'e!1ae ("e /+34 !!"a/le)+ !l'e!1a &'ses+a8e!&'ses+ ",e& &es&a"& &'ses

;$ & 9. !e'%!ae+ S. !e'%!ae+ C. !e'%!ae+ H.!l'e!1ae ("e /+34 !!"a/le)+ !l'e!1a &'ses+a8e!&'ses+


21/23

Ot)er Anti/iotis

ciproloxacin 10 mkd q 12 hr,

!o-trimoxa&ole -10 mk7 897 (+a,ed on B/) Tri@o/e 5 mg5m' atri# 160 mg5m' 0

mgta+ 0 mgta+ Maro/id 0mg5 m'

!lindamycin : 30 mk7 or o,teomyeliti, 30-50 mk7 q or 6 "ran#le,: >5mg5m' 150m'

!hloramphenicol 50-100 mk7 C)oro#6etin C)ora#o

Tetra6ine *%-7% #&D

Antaids

!imetidine 10-20 mk7 Tagamet ,yr 200mg5ml

100mg5m'

Lanitidine -5 mk7 q

Zantac 9< 50 mg2m' / 150mg 300 mg

mepra&ole 0.6-0.> mk 7Lose 20 mgta+ 0 mgta+

Hamotidine 0.> mkd q 12 H2Bloc 20mg2m'

'an&opra&ole 15-30 mg2 hr, 25 mg 7 / Prevacid H7B

Anti emeticetoclopramide 0.1 mkd q hr,

GLUCOSE IN9USION RATE

GIR, RATE B DEBTROSITY FB Q 60/EL9/%ELA' '9E: 5-6 !EBLA' '9E -12

7extro,ity d5 50

7 >.5 >5 710 100 750 500

!onDer,ion:!onc de,ired-act#al x 2 x total Dol 1000

Eg: d10- d5x2G 0.1

!onDer,ion: d>.5G 0.055 710G 0.11

!alorie,: 75 0.2 kcalcc

7>.5 0.3 710 0. 712 0.5


22/23

PULMONARY 8OLUMES

1. Botal


23/23

Ins0in Dri

Cec#re reg#lar in,#lin (100 i#m')

/repare a, ollo,:

1. a,pirate 0.1 m' rom Dial J 0.m' CC to make10 i#m'

2. a,pirate 0.1m' rom (1) J 0. CC to make1 i#m'

Ctart do,e at 0.05 i# k %

Ex. Feight 1.55 kg 1.55 x 0.05 G 0.0 m'%!alc#late or Dol nedded in ho#r, 0.0m' x G 0.6 m'

9n,tr#ction,: a,pirate 0.6 ml rom (2) J >.m' to

make m' and r#n at 1 m' ho#r

DOPA- DOU COCKTAIL

• "et rate o dopa according to de,ired do,e

• "et Dol#me o do+# according to de,ireddo,e #,ing

Medical Intern s Handy Notes

Documents

Transcript of Medical Intern s Handy Notes